TherapyPhotopheresis therapy for cutaneous T-cell lymphoma☆
References (27)
- et al.
Karyotype studies of cutaneous T cell lymphoma: evidence for clonal origin
J Invest Dermatol
(1979) - et al.
Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma
J Am Acad Dermatol
(1992) - et al.
Photopheresis for the treatment of cutaneous T cell lymphoma
J Am Acad Dermatol
(1990) - et al.
Parenteral administration of 8-methoxypsoralen in photopheresis
J Am Acad Dermatol
(1993) - et al.
Extracorporeal photochemotherapy induces the production of tumor necrosis factor-alpha by monocytes: implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis
J Invest Dermatol
(1992) - et al.
Mycosis fungoides: survival, prognostic features, response to therapy and autopsy findings
Medicine (Baltimore)
(1972) - et al.
Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up
J Clin Oncol
(1986) - et al.
Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides
Cancer
(1988) - et al.
Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: definition of three distinctive prognostic groups
Ann Intern Med
(1988) - et al.
Mycosis fungoides: clinicopathologic relationships, survival, and therapy in 59 patients with observations on occupation as a new prognostic factor
Cancer
(1980)
The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease: a study of 50 patients
J Clin Invest
Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy
N Engl J Med
Photopheresis update
Prog Dermatol
Cited by (133)
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): Part II. Prognosis, management, and future directions
2014, Journal of the American Academy of DermatologyCitation Excerpt :Later studies yielded a 35% to 71% ORR and a 14% to 26% CRR.122-126 Parameters associated with favorable response include short disease duration, clinical improvement in <6 months, normal CD8+ T cell count and CD4:CD8 ratio, low percentage of Sézary cells, and the absence of extracutaneous disease.122-127 Bexarotene or IFNα may be added for synergy.126,128-131
Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The hellenic experience
2012, Transfusion and Apheresis ScienceThe role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphomas
2012, Transfusion and Apheresis ScienceCitation Excerpt :The pivotal study was followed by a number of other studies both from American and European centers. The most important clinical studies that used ECP as monotherapy are shown in Table 1 [2,11–17]. The review of the results of the clinical studies mentioned above inevitably raises concerns, discussed in the following paragraphs:
Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma
2024, Expert Review of Anticancer TherapyEuropean dermatology forum – updated guidelines on the use of extracorporeal photopheresis 2020 – part 1
2020, Journal of the European Academy of Dermatology and Venereology
- ☆
Supported in part by a Physicians' Referral Service grant from the M. D. Anderson Cancer Center and by the Burnell Chaney Patient Education Fund.